Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
After finishing at $7.82 in the prior trading day, Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) closed at $7.85, up 0.38%. In other words, the price has increased by $0.38 from its previous closing price. On the day, 2.1 million shares were traded. AUPH stock price reached its highest trading level at $7.97 during the session, while it also had its lowest trading level at $7.475.
Ratios:
Our goal is to gain a better understanding of AUPH by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.39 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.81. For the most recent quarter (mrq), Quick Ratio is recorded 5.26 and its Current Ratio is at 5.93. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.18.
Oppenheimer Upgraded its Perform to Outperform on December 10, 2021, whereas the target price for the stock was revised from $33 to $31.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 07 ’25 when Keenan Greg sold 8,305 shares for $8.23 per share. The transaction valued at 68,350 led to the insider holds 153,484 shares of the business.
Greenleaf Peter sold 195,593 shares of AUPH for $1,564,744 on Mar 03 ’25. The Chief Executive Officer now owns 1,953,892 shares after completing the transaction at $8.00 per share. On Mar 04 ’25, another insider, Greenleaf Peter, who serves as the Chief Executive Officer of the company, sold 164,947 shares for $7.92 each. As a result, the insider received 1,306,380 and left with 1,788,945 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AUPH now has a Market Capitalization of 1060566400 and an Enterprise Value of 825892800. As of this moment, Aurinia’s Price-to-Earnings (P/E) ratio for their current fiscal year is 28.42, and their Forward P/E ratio for the next fiscal year is 10.36. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.29 while its Price-to-Book (P/B) ratio in mrq is 3.09. Its current Enterprise Value per Revenue stands at 3.34 whereas that against EBITDA is 13.337.
Stock Price History:
The Beta on a monthly basis for AUPH is 1.17, which has changed by 0.36048532 over the last 52 weeks, in comparison to a change of 0.11241627 over the same period for the S&P500. Over the past 52 weeks, AUPH has reached a high of $10.67, while it has fallen to a 52-week low of $5.08. The 50-Day Moving Average of the stock is -2.70%, while the 200-Day Moving Average is calculated to be 1.68%.
Shares Statistics:
The stock has traded on average 1.42M shares per day over the past 3-months and 1276930 shares per day over the last 10 days, according to various share statistics. A total of 137.75M shares are outstanding, with a floating share count of 120.13M. Insiders hold about 11.08% of the company’s shares, while institutions hold 43.62% stake in the company. Shares short for AUPH as of 1745971200 were 11248705 with a Short Ratio of 7.91, compared to 1743379200 on 11489144. Therefore, it implies a Short% of Shares Outstanding of 11248705 and a Short% of Float of 8.9899994.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
